We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where AVITA Medical Inc. (NASDAQ:RCEL) stands against the other cosmetic surgery and aesthetics stocks.
In the face of economic uncertainty, consumer preferences in the beauty industry are changing. A Bloomberg Intelligence poll conducted in June 2024 with 650 participants found that 40% of respondents gave beauty and personal care purchases more importance than other products. Nonetheless, this represents the lowest result since the survey’s launch two years ago, a 10-percentage-point drop from January.
Despite the continued success of premium cosmetic products, there is less demand for mainstream, reasonably priced products, which make up the majority of the market. Leonard Lauder’s “Lipstick Index” theory, which associates economic slowdowns with increased spending on self-care, seems less sound these days. Although the beauty industry has grown significantly over the last five years, Andrea Felsted, a Bloomberg Opinion columnist, observes that customer interests are beginning to shift.
This drop in affordable beauty purchases raises questions about how well the industry can withstand economic downturns. The results point to changing customer behavior, with high-end products performing better and less expensive markets being squeezed during difficult economic conditions.
Amidst this shift, according to Ulta CEO Dave Kimbell, younger generations, Gen Z and Gen Alpha, are more willing to spend money on beauty than previous generations, especially on skincare or as a way to express themselves. He also mentioned that a growing percentage of Americans are Hispanic consumers, who are more likely to be active in the area. Here are some comments from Kimbell:
“While we anticipate that some of these headwinds will persist in the near term, we are confident in our ability to deliver on our plans and set ourselves up for long-term growth.”
Meanwhile, the market for medical aesthetics, or procedures meant to enhance patients’ physical attractiveness, is expected to grow in the future. According to research by senior partner Olivier Leclerc and colleagues, the CAGR for neuromodulators like Botox is anticipated to reach 11.9 percent in the US and Canada by 2025. By 2025, the compound annual growth rate for injectable dermal fillers, such as biostimulators and hyaluronic acid fillers, may reach 3.8 percent. Moreover, as per McKinsey’s research report, through 2025, the medical aesthetics industry is expected to continue growing at a rate close to double digits.
In one of the recent developments, finance solutions like “buy-now, pay-later” loans are being given to make cosmetic procedures more affordable because of the rising demand for these procedures in the United States, as reported by Bloomberg. While the demand spike from the pandemic has subsided, rates of aesthetic procedures are still substantially higher than they were before COVID, with a 2023 increase over 2024, according to a June 2024 study from the American Society of Plastic Surgeons.
Financing programs that divide expenses ranging from $200 to $10,000 into smaller installments over three to sixty months are now advantageous for facial procedures and other treatments. These choices are especially appealing to younger consumers because they frequently include interest-free terms and low credit requirements. According to Bloomberg, sales of asset-backed securities in the United States have increased by almost 20% year over year, reflecting this trend in the larger financial market. This highlights the connection between high customer demand and innovative financial solutions.
Our Methodology:
In this article, we first used a stock screener, to list down all Cosmetic Surgery and Aesthetics Stocks (as of the writing of this article) with the highest institutional ownership. From the resultant dataset, we chose 11 stocks with the highest number of hedge fund investors, using Insider Monkey’s database of 900 hedge funds in Q3 2024 to gauge hedge fund sentiment for stocks.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here)
A product engineer operating proprietary machinery used to create small samples of a patient’s skin.
AVITA Medical Inc. (NASDAQ:RCEL)
Number of Hedge Fund Investors: 3
One of the Best Aesthetics Stocks, AVITA Medical, Inc. (NASDAQ:RCEL) is a regenerative medicine company that operates in the United Kingdom, Japan, Australia, and the United States. The company provides regenerative treatments to treat medical issues such as burn injuries, traumatic injuries, chronic wounds, and skin and aesthetic concerns like vitiligo and anomalies of full-thickness skin. By using less donor skin and transforming a patient’s skin cells into a spray-on solution for healing and repigmentation, the RECELL technique speeds up recovery.
Strong Q3 2024 financial results and business updates from AVITA Medical, Inc. (NASDAQ:RCEL) have shown the company’s encouraging growth trajectory and prospects. The business recorded $19.5 million in commercial revenue, a strong 44% growth from the previous year, and an outstanding gross profit margin of 83.7%. This was fueled by the switch to RECELL GO, increased market share in current accounts, and the acquisition of new clients for the treatment of full-thickness skin defects. These margins are impressive for an organization of Avita’s scale, even though they are slightly lower than the previous year due to the engineering and validation costs associated with the RECELL GO platform. As of September 30, 2024, the company has $44.4 million in cash on hand, putting it in a great position to execute its strategic ambitions.
AVITA Medical, Inc. (NASDAQ:RCEL) anticipates 58%-72% revenue growth in Q4 2024 and plans to achieve GAAP profitability by Q3 2025, backed by excellent execution and creative solutions like RECELL GO. Its high margins and excellent pipeline make it an attractive investment option despite rising costs.
D. E. Shaw’s D E Shaw was the largest stakeholder in the company from among the funds in Insider Monkey’s database at the end of Q3 2024. It owns 67,096 shares worth $719,269 as of Q3.
Overall RCEL ranks 11th on our list of the best cosmetic surgery and aesthetics stocks to invest in now. While we acknowledge the potential for RCEL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than RCEL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
